{
    "id": 26665,
    "fullName": "CAD - ALK",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CAD-ALK results from the fusion of CAD and ALK (PMID: 26633560). CAD-ALK has been identified in colorectal cancer (PMID: 26633560), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 4305,
                    "pubMedId": 26633560,
                    "title": "Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26633560"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 790,
        "geneSymbol": "CAD",
        "terms": [
            "CAD",
            "CDG1Z",
            "EIEE50",
            "GATD4"
        ]
    },
    "variant": "CAD - ALK",
    "createDate": "06/28/2017",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11319,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal cancer patient harboring CAD-ALK was sensitive to treatment with Rozlytrek (entrectinib), demonstrating a 38% decrease in target lesion size (PMID: 26633560).",
            "molecularProfile": {
                "id": 27957,
                "profileName": "CAD - ALK"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4305,
                    "pubMedId": 26633560,
                    "title": "Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26633560"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27957,
            "profileName": "CAD - ALK",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}